Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

David Kuang-Fu Chang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4821-3078; OpenAlex author ID A5009039019, A5133573515. Sources: ClinicalTrials.gov.

Their work

Papers
76 (first author 8, last author 10)
Trials
2 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
296
Papers, trials and grants by year

2011: 2 papers · 2012: 5 papers · 2013: 2 papers · 2014: 7 papers · 2015: 6 papers · 2016: 6 papers · 2017: 5 papers, 1 trial · 2018: 2 papers · 2019: 4 papers · 2020: 6 papers · 2021: 9 papers · 2022: 5 papers · 2023: 2 papers · 2024: 4 papers, 1 trial · 2025: 7 papers · 2026: 4 papers

Papers 50 of 76

  1. Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.09.027↗
  2. Clinical and molecular landscape of surgically resected early onset pancreatic cancer. Last author DOI 10.1093/bjs/znag032↗
  3. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  4. Morphospatial profiling of cancer-associated fibroblasts reveals architectural subtypes of pancreatic ductal adenocarcinoma Last author DOI 10.64898/2026.02.06.704414↗
  5. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  6. Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41416-025-03051-z↗
  7. Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathw… Co-author DOI 10.1038/s41598-025-95766-5↗
  8. Multi-protein panel in pancreatic cyst fluid for improved risk stratification for pancreatic cancer Co-author DOI 10.1101/2025.09.17.25335852↗
  9. KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition. Co-author DOI 10.1158/0008-5472.can-23-2709↗
  10. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. Co-author DOI 10.1186/s12885-024-13333-z↗
  11. Targeting myeloid cells in pancreatic ductal adenocarcinoma: from primary tumors to liver metastasis. Co-author DOI 10.3389/fimmu.2025.1555036↗
  12. Qualitative flow metabolic phenotype of pancreatic cancer. A new prognostic biomarker? Co-author DOI 10.1016/j.hpb.2023.11.010↗
  13. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC. Co-author DOI 10.1038/s41598-024-59451-3↗
  14. nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer Co-author DOI 10.1101/2024.09.23.614610↗
  15. Integrating metabolic profiling of pancreatic juice with transcriptomic analysis of pancreatic cancer tissue identifies distinct clinical subgroups. Co-author DOI 10.3389/fonc.2024.1405612↗
  16. Artificial Intelligence in Pancreatic Ductal Adenocarcinoma Imaging: A Commentary on Potential Future Applications. Co-author DOI 10.1053/j.gastro.2023.04.003↗
  17. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  18. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Last author DOI 10.1016/s1470-2045(21)00703-8↗
  19. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  20. CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s13046-022-02443-w↗
  21. Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer. Last author DOI 10.3390/cancers14215302↗
  22. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Co-author PMID 36628279↗
  23. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Co-author DOI 10.1016/j.annonc.2020.11.013↗
  24. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Co-author DOI 10.1038/s41467-021-27099-6↗
  25. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  26. Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. Co-author DOI 10.1053/j.gastro.2021.06.080↗
  27. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  28. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. Co-author DOI 10.1200/jco.20.03238↗
  29. Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers13153820↗
  30. Role of PLEXIND1/TGFβ Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS. Co-author DOI 10.3390/cancers13164048↗
  31. Molecular Subtyping and Precision Medicine for Pancreatic Cancer. Last author DOI 10.3390/jcm10010149↗
  32. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Co-author DOI 10.1002/1878-0261.12743↗
  33. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.05.010↗
  34. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  35. PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer. Last author DOI 10.1016/j.clon.2019.07.011↗
  36. Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. Last author DOI 10.1016/j.clon.2019.08.007↗
  37. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000003143↗
  38. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Co-author DOI 10.1002/path.5320↗
  39. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗
  40. Molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/s41575-019-0109-y↗
  41. Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Last author DOI 10.21037/cco.2019.04.06↗
  42. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Co-author DOI 10.1038/s41389-018-0096-9↗
  43. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  44. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Co-author DOI 10.1038/bjc.2017.40↗
  45. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Co-author DOI 10.1038/ncomms14294↗
  46. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ng.3861↗
  47. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  48. Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. First author DOI 10.1158/1078-0432.ccr-16-2411↗
  49. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2016.04.014↗
  50. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2016.271↗

Trials 2

  1. A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer Study chair NCT06498518↗
  2. Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer Principal investigator NCT04161417↗

Closest collaborators

The 25 strongest of 296 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Victor Biankin · 55 shared papers, 2011–2026 · strength 4.65
  2. Stephan B. Dreyer · 12 shared papers, 2017–2026 · strength 1.80
  3. Fieke E. M. Froeling · 8 shared papers, 2021–2026 · strength 1.55
  4. Nigel Balfour Jamieson · 15 shared papers, 2014–2026 · strength 1.50
  5. Peter J. Bailey · 15 shared papers, 2014–2022 · strength 1.02
  6. Christian P. Pilarsky · 7 shared papers, 2012–2025 · strength 0.88
  7. Colin J. McKay · 8 shared papers, 2014–2026 · strength 0.88
  8. Antonio Pea · 6 shared papers, 2021–2025 · strength 0.84
  9. Aldo Scarpa · 8 shared papers, 2014–2025 · strength 0.79
  10. Anthony James Gill · 13 shared papers, 2012–2025 · strength 0.78
  11. Amber L. Johns · 13 shared papers, 2012–2025 · strength 0.77
  12. Jennifer P. Morton · 9 shared papers, 2014–2025 · strength 0.77
  13. Jaswinder Singh Samra · 11 shared papers, 2012–2025 · strength 0.73
  14. Adam S. Bryce · 3 shared papers, 2022–2026 · strength 0.73
  15. Owen James Sansom · 8 shared papers, 2014–2025 · strength 0.70
  16. Jeff Evans · 1 shared trial, 2024 · strength 0.68
  17. Raffaella Casolino · 5 shared papers, 2021–2022 · strength 0.60
  18. Sean Michael Grimmond · 15 shared papers, 2012–2018 · strength 0.60
  19. Debabrata Mukhopadhyay · 4 shared papers, 2021–2025 · strength 0.58
  20. Hemant Mahendrakumar Kocher · 4 shared papers, 2018–2025 · strength 0.55
  21. Steve Gallinger · 4 shared papers, 2017–2026 · strength 0.51
  22. Marina Pajic · 13 shared papers, 2011–2020 · strength 0.50
  23. Rita Teresa Lawlor · 5 shared papers, 2014–2025 · strength 0.49
  24. Michèle Milella · 4 shared papers, 2021–2022 · strength 0.43
  25. Robert Grützmann · 4 shared papers, 2012–2025 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.